These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 26201504)

  • 21. Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy.
    Narang I; Kadmon G; Lai D; Dhanju S; Kirby-Allen M; Odame I; Amin R; Lu Z; Al-Saleh S
    Ann Am Thorac Soc; 2015 Jul; 12(7):1044-9. PubMed ID: 25970812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic profile of the anti-sickling hydroxyurea in wild-type and transgenic sickle cell mice.
    Iyamu WE; Lian L; Asakura T
    Chemotherapy; 2001; 47(4):270-8. PubMed ID: 11399864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia.
    Silva DG; Belini Junior E; Torres Lde S; Ricci Júnior O; Lobo Cde C; Bonini-Domingos CR; de Almeida EA
    Blood Cells Mol Dis; 2011 Jun; 47(1):23-8. PubMed ID: 21489839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An age dependent response to hydroxyurea in pediatric sickle cell anemia patients with alpha thalassemia trait.
    Figueiredo L; Morrone K; Wei C; Ireland K; Cohen HW; Driscoll C; Manwani D
    Blood Cells Mol Dis; 2017 Jul; 66():19-23. PubMed ID: 28783617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale and design of mDOT-HuA study: a randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania.
    Makubi A; Sasi P; Ngaeje M; Novelli EM; Mmbando BP; Gladwin MT; Makani J
    BMC Med Res Methodol; 2016 Oct; 16(1):140. PubMed ID: 27756209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of fixed low dose hydroxyurea in Indian children with sickle cell anemia: a single centre experience.
    Jain DL; Apte M; Colah R; Sarathi V; Desai S; Gokhale A; Bhandarwar A; Jain HL; Ghosh K
    Indian Pediatr; 2013 Oct; 50(10):929-33. PubMed ID: 23798623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients.
    Chenou F; Hounkpe BW; Domingos IF; Tonassé WV; Batista THC; Santana RM; Arcanjo GDS; Alagbe AE; Araújo ADS; Lucena-Araújo AR; Bezerra MAC; Costa FF; Sonati MF; De Paula EV; Dos Santos MNN
    Ann Hematol; 2021 Nov; 100(11):2669-2676. PubMed ID: 34453189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of a cohort of Angolan children with sickle cell anemia treated with hydroxyurea.
    Santos B; Ginete C; Gonçalves E; Delgadinho M; Miranda A; Faustino P; Arez AP; Brito M
    Blood Cells Mol Dis; 2024 Mar; 105():102822. PubMed ID: 38215581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
    Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
    Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia.
    Hankins JS; Aygun B; Nottage K; Thornburg C; Smeltzer MP; Ware RE; Wang WC
    Medicine (Baltimore); 2014 Dec; 93(28):e215. PubMed ID: 25526439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision.
    Creary S; Zickmund S; Ross D; Krishnamurti L; Bogen DL
    BMC Res Notes; 2015 Aug; 8():372. PubMed ID: 26303306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation.
    Boucher AA; Dong M; Vinks AA; Marahatta A; Howard TA; Ware RE; Nathan JD; Abu-El-Haija M; Luchtman-Jones L
    J Clin Pharmacol; 2021 Apr; 61(4):547-554. PubMed ID: 33029796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
    Maia Filho PA; Pereira JF; Almeida Filho TP; Cavalcanti BC; Sousa JC; Lemes RPG
    Environ Mol Mutagen; 2019 Apr; 60(3):302-304. PubMed ID: 30525240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of telehealth visits on hydroxyurea response in sickle cell anemia.
    Shaner S; Hilliard L; Howard T; Pernell B; Bhatia S; Lebensburger J
    Pediatr Blood Cancer; 2021 Dec; 68(12):e29354. PubMed ID: 34532949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey.
    Colombatti R; Palazzi G; Masera N; Notarangelo LD; Bonetti E; Samperi P; Barone A; Perrotta S; Facchini E; Miano M; Del Vecchio GC; Guerzoni ME; Corti P; Menzato F; Cesaro S; Casale M; Rigano P; Forni GL; Russo G; Sainati L;
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28868627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxyurea in children: present and future.
    Vichinsky EP
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of hydroxyurea on lymphocyte subsets in children with sickle cell anemia.
    Elsayh KI; Saad K; Hetta HF; Youssef MAM; Embaby MM; Mohamed IL; Abdel-Aziz SM; Zahran ZAM; Elhoufey A; Ghandour AMA; Zahran AM
    Pediatr Res; 2023 Mar; 93(4):918-923. PubMed ID: 34897281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of hydroxyurea in children with sickle cell disease: what comes next?
    Ohene-Frempong K; Smith-Whitley K
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
    Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A
    Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.